|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Manganese tetroxide (as Mn) | CAS 1317-35-7 | ||
| Mn3O4 | RTECS OP0895000 | ||
|
Synonyms & Trade Names Manganese oxide, Manganomanganic oxide, Trimanganese tetraoxide, Trimanganese tetroxide |
DOT ID & Guide |
||
|
Exposure Limits |
NIOSH REL: See Appendix D | ||
| OSHA PEL�: C 5 mg/m3 | |||
| IDLH N.D. | Conversion | ||
|
Physical Description Brownish-black powder. [Note: Fumes are generated whenever manganese oxides are heated strongly in air.] |
|||
|
MW: 228.8 |
BP: ? |
MLT: 2847°F |
Sol: Insoluble |
|
VP: 0 mmHg (approx) |
IP: NA |
|
Sp.Gr: 4.88 |
|
Fl.P: NA |
UEL: NA |
LEL: NA |
|
|
Incompatibilities & Reactivities Soluble in hydrochloric acid (liberates chlorine gas) |
|||
|
Measurement Methods NIOSH 7300; OSHA ID121, ID125G |
|
Personal Protection & Sanitation Skin: No recommendation Eyes: No recommendation Wash skin: No recommendation Remove: No recommendation Change: Daily |
First Aid (See procedures) Eye: Irrigate immediately Skin: Soap wash Breathing: Respiratory support Swallow: Medical attention immediately |
| Respirator Recommendations To be added later | |
| Exposure Routes inhalation, ingestion, skin and/or eye contact | |
| Symptoms Asthenia, insomnia, mental confusion; low-back pain; vomiting; malaise (vague feeling of discomfort), lassitude (weakness, exhaustion); kidney damage; pneumonitis | |
|
Target Organs
respiratory system, central nervous system, blood, kidneys |
|
| See also: INTRODUCTION |